TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

North Am 2006;20:155-74.
21.176 Nash KL et al. Managing hepatitis C infection. Br Med J 2009;339:37-42.
21.177 Hellard M et al. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin
Infect Dis 2009;49:561-73.
21.178 Coffin CS et al. Management of patients co-infected with HBV and HCV. Expert Rev Anti Infect
Ther 2009;7:549-58.
21.179 Heller T et al. Acute hepatitis C: a multifaceted disease. Semin Liver Dis 2005;25:7-17.
21.180 Ozaras R et al. Acute hepatitis C: prevention and treatment. Expert Rev Anti Infect Ther 2009;7:
351-61.
21.181 Wiegand J et al. Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon
α. J Antimicrob Chemother 2008;62:860-5.
21.182 Maheshwari A et al. Acute hepatitis C. Lancet 2008;372:321-32.
21.183 Dionne-Odom J et al. Acute hepatitis C and HIV coinfection. Lancet Infect Dis 2009;9:775-83.
21.184 Vogel M et al. Treatment of acute hepatitis C in HIV-infection. J Antimicrob Chemother 2010;65:4-
9.
21.185 Cox AL et al. Prospective evaluation of community acquired acute phase hepatitis C virus infection.
Clin Infect Dis 2005;40:951-8.
21.186 Scott JD et al. Molecular diagnostics of hepatitis C virus infection. A systematic review. J Am Med
As-soc 2007;297:724-32.
21.187 De Rosa FG et al. 12-week treatment of acute hepatitis C virus with pegylated interferon-α-2b in injection
drug users. Clin Infect Dis 2007;45:583-8.
21.188 Hardikar W et al. Treatment options for chronic hepatitis B and C in children. Expert Rev Anti Infect
Ther 2006;4:583-91.
21.189 Davis GL et al. Treatment of chronic hepatitis C infection: one step at a time. Lancet Infect Dis 2005;
5:524-6.
21.190 Marcus EL et al. Chronic hepatitis C virus infection in older adults. Clin Infect Dis 2005;41:1606-12.
21.191 McGinn TG et al. Treating chronic hepatitis C in the primary care setting. Semin Liver Dis 2005;25:
65-71.
21.192 Patel K et al. Diagnosis and treatment of chronic hepatitis C infection. Br Med J 2006;332:1013-7.
21.193 Oh S et al. Antiviral therapy for treatment naïve patients with hepatitis C virus. Infect Dis Clin North
Am 2006;20:99-113.
21.194 Mallolas J et al. Pegylated IFN-α2a for treatment-naïve patients coinfected with HCV and HIV. Expert
Rev Anti Infect Ther 2008;6:281-9.
21.195 Aghemo A et al. Pegylated IFN-α2a and ribavirin in the treatment of hepatitis C. Expert Rev Anti Infect
Ther 2009;7:925-35.
21.196 Berenguer J et al. Pegylated interferon α2a plus ribavirin versus pegylated interferon α2b plus ribavirin
for the treatment of chronic hepatitis C in HIV-infected patients. J Antimicrob Chemother 2009;
63:1256-63.
21.197 McHutchison JG et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
N Engl J Med 2009;361:580-93.
21.198 Hoofnagle JH et al. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:2444-
51.
21.199 Keating GM et al. Peginterferon α-2a (40KD) plus ribavirin. A review of its use in the management of
patients with chronic hepatitis C and and persistently ‗normal‘ ALT levels. Drugs 2005;65:521-36.
21.200 Ahn J et al. Peginterferon-α2b and ribavirin. Expert Rev Anti Infect Ther 2004;2:17-25.
21.201 Vogel W. Peginterferon-α2a (40kDa)/ribavirin combination for the treatment of chronic hepatitis C infection.
Expert Rev Anti Infect Ther 2003;1:423-31.
21.202 Jara P et al. Efficacy and safety of peginterferon-α2b and ribavirin combination therapy in children
with chronic hepatitis C infection. Pediatr Infect Dis J 2008;27:142-8.
21.203 Keeffe EB. Chronic hepatitis C: management of treatment failures. Clin Gastroenterol Hepatol
2005;3(suppl. 2):S102-5.
21.204 Sethi A et al. Approach to the management of patients with chronic hepatitis C who failed to achieve
sustained virologic response. Infect Dis Clin North Am 2006;20:115-35.
21.205 Ahmed F et al. Treatment of relapsers after combination therapy for chronic hepattitis C. Infect Dis
Clin North Am 2006;20:137-53.
21.206 Bailly F et al. Management of nonresponsive hepatitis C. Expert Rev Anti Infect Ther 2010;8:379-
95.
21.207 Mangia A et al. Peginterferon alfa-2b and ribavirin for 12 versus 24 weeks in HCV genotype 2 or 3. N
Engl J Med 2005;352:2609-17.
21.208 Shiffmann ML et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N
Engl J Med 2007;357:124-34.
21.209 Dalton HR et al. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis 2008;8:
698-709.
21.210 Teo CG. Much meat, much malady: changing perceptions of the epidemiology of hepatitis E. Clin Microbiol
Infect 2010;16:24-32.
21.211 Bihl F et al. Hepatitis E virus: a zoonosis adapting to humans. J Antimicrob Chemother 2010;65:
817-21.
21.212 Emerson SU et al. Hepatitis E. Pediatr Infect Dis J 2007;26:1147-8.
21.213 Kamar N et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med
2008;358:811-7.
21.214 Focher F et al. Sensitivity of monkey B virus (cercopithecine herpesvirus 1) to antiviral drugs: role of
thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides. Antimicrob
Agents Chemother 2007;51:2028-34.
21.215 Jainkittivong A et al. Herpes B virus infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod
1998;85:399-403.
21.216 Huff JL et al. B virus (cercopithecine herpesvirus 1) infection in humans and macaques: potential for
zoonotic disease. Emerg Infect Dis 2003;9:246-50.
21.217 National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention
(CDC). Cercopithecine herpesvirus 1 (B virus) infection resulting from ocular exposure. Available
at: http://www.cdc.gov/niosh/docs/99-100/pdfs/99-100.pdf. Accessed on August 27 th 2010.
21.218 Cohen JI et al. Recommendations for prevention of and therapy for exposure to B virus (cercopithecine
herpesvirus 1). Clin Infect Dis 2002;35:1191-203.
21.219 Wilson SS et al. Novel approaches in fighting herpes simplex virus infections. Expert Rev Anti Infect